China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi. The funds will be directed towards the Investigational New Drug (IND) filing for the company’s innovative CAR-T cell therapy and the advancement of automated production processes, as well as accelerating the clinical translation of metabolically armored solid tumor cell therapies.
Investment and Development Goals
The proceeds from the Series A financing will significantly bolster Leman Biotech’s efforts in developing its extremely low-dose, metabolically armored chimeric endocrine receptor T (CAR-T) cell therapy. This investment underscores the company’s commitment to pushing the boundaries of cancer immunotherapy through cutting-edge research and development.
Leman Bio’s Innovative Approach
Leman Bio, co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, is at the forefront of combining innovative metabolic reprogramming technology with an advanced AI drug discovery platform. The company’s Meta 10 core technology is a metabolic reprogramming platform that effectively overcomes T cell exhaustion and induces the formation of memory-like immune cells in pre-clinical studies. Its lead program, Meta10-19, a metabolically armored CD19 CAR-T cell therapy, has completed an investigator-initiated trial (ITT) with positive preliminary results, highlighting the potential of this next-generation therapy.-Fineline Info & Tech
Leave a Reply